470 related articles for article (PubMed ID: 33210986)
1. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
Iaffaldano P; Lucisano G; Patti F; Brescia Morra V; De Luca G; Lugaresi A; Zaffaroni M; Inglese M; Salemi G; Cocco E; Conte A; Ferraro D; Galgani S; Bergamaschi R; Pozzilli C; Salvetti M; Lus G; Rovaris M; Maniscalco GT; Logullo FO; Paolicelli D; Achille M; Marrazzo G; Lovato V; Comi G; Filippi M; Amato MP; Trojano M;
Mult Scler; 2021 Mar; 27(3):430-438. PubMed ID: 33210986
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.
Tedeholm H; Piehl F; Lycke J; Link J; Stawiarz L; Burman J; de Flon P; Fink K; Gunnarsson M; Mellergård J; Nilsson P; Sundström P; Svenningsson A; Johansson H; Andersen O
Mult Scler Relat Disord; 2022 Dec; 68():104220. PubMed ID: 36242804
[TBL] [Abstract][Full Text] [Related]
3. Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register.
Iaffaldano P; Lucisano G; Guerra T; Patti F; Onofrj M; Brescia Morra V; Zaffaroni M; Pozzilli C; Cocco E; Sola P; Salemi G; Inglese M; Bergamaschi R; Gasperini C; Conte A; Salvetti M; Lus G; Maniscalco GT; Totaro R; Vianello M; Granella F; Ferraro E; Aguglia U; Gatto M; Sangalli F; Chisari CG; De Luca G; Carotenuto A; Baroncini D; Colombo D; Nica M; Paolicelli D; Comi G; Filippi M; Amato MP; Trojano M
Mult Scler; 2022 Dec; 28(14):2243-2252. PubMed ID: 35971322
[TBL] [Abstract][Full Text] [Related]
4. Risk of secondary progressive multiple sclerosis after early worsening of disability.
Dzau W; Sharmin S; Patti F; Izquierdo G; Eichau S; Prat A; Girard M; Duquette P; Onofrj M; Lugaresi A; Ozakbas S; Gerlach O; Boz C; Grammond P; Terzi M; Amato MP; La Spitaleri D; Ramo-Tello C; Maimone D; Cartechini E; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Iuliano G; Soysal A; Kalincik T
J Neurol Neurosurg Psychiatry; 2023 Dec; 94(12):984-991. PubMed ID: 37414538
[TBL] [Abstract][Full Text] [Related]
5. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
6. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
[TBL] [Abstract][Full Text] [Related]
7. Application of definitions for conversion to secondary progressive MS in a Danish nationwide population.
Kopp TI; Bramow S; Illes Z; Kant M; Kristensen C; Rasmussen PV; Sellebjerg F; Magyari M
Mult Scler Relat Disord; 2021 Nov; 56():103319. PubMed ID: 34666241
[TBL] [Abstract][Full Text] [Related]
8. Results from SPECTRUM: A survey of healthcare professionals to understand current diagnosis and management practices for secondary progressive multiple sclerosis in the United Kingdom.
Duddy M; Wilkinson C; Medhurst S; Rhys K
Mult Scler Relat Disord; 2021 Oct; 55():103174. PubMed ID: 34399317
[TBL] [Abstract][Full Text] [Related]
9. Natural history of secondary-progressive multiple sclerosis.
Tremlett H; Yinshan Zhao ; Devonshire V
Mult Scler; 2008 Apr; 14(3):314-24. PubMed ID: 18208898
[TBL] [Abstract][Full Text] [Related]
10. Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals.
Boyko A; Therapontos C; Horakova D; Szilasiová J; Kalniņa J; Kolontareva J; Gross-Paju K; Selmaj K; Sereike I; Milo R; Gabelić T; Rot U
Mult Scler Relat Disord; 2021 May; 50():102778. PubMed ID: 33592384
[TBL] [Abstract][Full Text] [Related]
11. Disease-modifying treatment, long-term outcomes and transition to progressive multiple sclerosis: data based on the New York State MS Consortium.
Jakimovski D; Kavak KS; Coyle PK; Goodman AD; Gottesman M; Zivadinov R; Weinstock-Guttman B;
J Neurol; 2024 Feb; 271(2):711-722. PubMed ID: 37995009
[TBL] [Abstract][Full Text] [Related]
12. Early predictors of conversion to secondary progressive multiple sclerosis.
Barzegar M; Najdaghi S; Afshari-Safavi A; Nehzat N; Mirmosayyeb O; Shaygannejad V
Mult Scler Relat Disord; 2021 Sep; 54():103115. PubMed ID: 34216997
[TBL] [Abstract][Full Text] [Related]
13. Clinical characterization of long-term multiple sclerosis (COLuMbus) patients in Argentina: A cross-sectional non-interventional study.
Deri N; Barboza A; Vrech C; Rey R; Burgos M; Fiol M; CalvoVildoso C; Patrucco L; Jose G; Aliberti P; Chirico D; Federico MB; Seifer G; Piedrabuena R
Mult Scler Relat Disord; 2024 Mar; 83():105421. PubMed ID: 38244525
[TBL] [Abstract][Full Text] [Related]
14. Identification and diagnosis of Secondary Progressive Multiple Sclerosis during the clinical encounter: Results from a physician survey.
Alvarez E; Nair KV; Gorritz M; Bartolome L; Maloney H; Ding Y; Golan T; Wade RL; Kumar R; Su W; Shah R; Russo P
Mult Scler Relat Disord; 2021 May; 50():102858. PubMed ID: 33799068
[TBL] [Abstract][Full Text] [Related]
15. Risk of secondary progressive multiple sclerosis: A longitudinal study.
Fambiatos A; Jokubaitis V; Horakova D; Kubala Havrdova E; Trojano M; Prat A; Girard M; Duquette P; Lugaresi A; Izquierdo G; Grand'Maison F; Grammond P; Sola P; Ferraro D; Alroughani R; Terzi M; Hupperts R; Boz C; Lechner-Scott J; Pucci E; Bergamaschi R; Van Pesch V; Ozakbas S; Granella F; Turkoglu R; Iuliano G; Spitaleri D; McCombe P; Solaro C; Slee M; Ampapa R; Soysal A; Petersen T; Sanchez-Menoyo JL; Verheul F; Prevost J; Sidhom Y; Van Wijmeersch B; Vucic S; Cristiano E; Saladino ML; Deri N; Barnett M; Olascoaga J; Moore F; Skibina O; Gray O; Fragoso Y; Yamout B; Shaw C; Singhal B; Shuey N; Hodgkinson S; Altintas A; Al-Harbi T; Csepany T; Taylor B; Hughes J; Jun JK; van der Walt A; Spelman T; Butzkueven H; Kalincik T
Mult Scler; 2020 Jan; 26(1):79-90. PubMed ID: 31397221
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying Therapies.
Hernandez L; O'Donnell M; Postma M;
Pharmacoeconomics; 2021 Feb; 39(2):243-256. PubMed ID: 32989685
[TBL] [Abstract][Full Text] [Related]
17. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
Lizak N; Malpas CB; Sharmin S; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Lugaresi A; Duquette P; Girard M; Prat A; Larochelle C; Trojano M; Grand'Maison F; Grammond P; Sola P; Ferraro D; Hupperts R; Bergamaschi R; Boz C; Van Pesch V; Spitaleri D; Terzi M; Kalincik T;
JAMA Neurol; 2020 Nov; 77(11):1398-1407. PubMed ID: 32716480
[TBL] [Abstract][Full Text] [Related]
18. Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
Pokryszko-Dragan A; Gruszka E; Bilińska M; Dubik-Jezierzańska M
Neurol Neurochir Pol; 2008; 42(1):6-11. PubMed ID: 18365957
[TBL] [Abstract][Full Text] [Related]
19. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
